Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review

Insights into Imaging

Table 10 Percentage change in ADC after NST

First author	After N cycles	pCR versus non-pCR (mean ± SD%)	ADC percentage change cutoff (%)	ADC ratio pCR versus non pCR^a	AUC
ΔADC %
Santamaria [27]	Post (~ 6 cycles)			1.788 ± 0.299 versus 1.487 ± 0.473 p = 0.009	0.73
Shin [26]	Post	81.3 versus 12.6 p < 0.001	40.7^b		0.96
Partridge [23]	Post	Overall: 64 ± 49 versus 50 ± 47; p = 0.013			0.61
		HR−/HER2−: 68 ± 32 versus 39 ± 39; p < 0.001			0.75
		HR+/HER2−: 82 ± 41 versus 54 ± 50; p = 0.01			0.71
		HR−/HER2+: 63 ± 79 versus 28 ± 46; p = 0.56			0.62
		HR+/HER2+: 43 ± 37 versus 61 ± 47; p = 0.64			0.55

ADC apparent diffusion coefficient, AUC area under the curve, HER2 human epidermal growth factor receptor 2, HR hormone receptor, pCR pathological complete response, Δ representing change
^a\(\frac{{\text{ADC}}_{{\text{mean}}\, {\text{post}}}}{{\text{ADC}}_{{\text{mean}} \,{\text{pre}}}}\)
^bcorresponding to a sensitivity of 100% and specificity of 91%